SMO and ovarian carcinoma: Importantly, a clinical trial using GDC-0049 (Vismodegib), a small-molecule inhibitor of Smo, recently carried out in patients with epithelial ovarian cancer in second or third remission, did not show any increase in progression-free survival for vismodegib maintenance versus placebo.